Optimal Treatment of Vasomotor Symptoms Due to Menopause and the Need for Effective
Patient-Provider Communications
Post-Test/Evaluation

Exit Survey
Questions marked with a * are required
20%
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Janine is a 48-year-old female who has been struggling with vasomotor symptoms, specifically hot flashes and night sweats, for the past 2 years. She has visited her gynecologist and is not interested in taking hormonal drugs. Which of the following would be an alternative option?
Rebecca is a 53-year-old female with vasomotor symptoms. She has a history of breast cancer in her family so her gynecologist prefers to put her on a neurokinin 3 (NK3) receptor antagonist. Which of the following is a US Food and Drug Administration (FDA)-approved NK3 receptor antagonist?
At what age should women be when gynecologists consider initiating conversations about vasomotor
symptoms and menopause?
Powered by QuestionPro